Green Owl Capital Management buys $2.2 Million stake in Radius Health Inc (RDUS)

Radius Health Inc (RDUS) : Green Owl Capital Management scooped up 41,963 additional shares in Radius Health Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 12, 2016. The investment management firm now holds a total of 71,963 shares of Radius Health Inc which is valued at $2.2 Million.Radius Health Inc makes up approximately 5.15% of Green Owl Capital Management’s portfolio.

Other Hedge Funds, Including , New England Private Wealth Advisors sold out all of its stake in RDUS during the most recent quarter. The investment firm sold 5,000 shares of RDUS which is valued $152,400. Trexquant Investment Lp sold out all of its stake in RDUS during the most recent quarter. The investment firm sold 13,596 shares of RDUS which is valued $414,406.Profund Advisors reduced its stake in RDUS by selling 4,615 shares or 18.67% in the most recent quarter. The Hedge Fund company now holds 20,101 shares of RDUS which is valued at $621,724. Radius Health Inc makes up approx 0.03% of Profund Advisors’s portfolio.California Public Employees Retirement System boosted its stake in RDUS in the latest quarter, The investment management firm added 85,000 additional shares and now holds a total of 121,800 shares of Radius Health Inc which is valued at $3.8 Million. Radius Health Inc makes up approx 0.01% of California Public Employees Retirement System’s portfolio.American Century Companies Inc boosted its stake in RDUS in the latest quarter, The investment management firm added 8,334 additional shares and now holds a total of 41,377 shares of Radius Health Inc which is valued at $1.3 Million.

Radius Health Inc opened for trading at $32.08 and hit $33.76 on the upside on Friday, eventually ending the session at $33.73, with a gain of 5.27% or 1.69 points. The heightened volatility saw the trading volume jump to 5,14,302 shares. Company has a market cap of $1,452 M.

On the company’s financial health, Radius Health Inc reported $-0.94 EPS for the quarter, missing the analyst consensus estimate by $ -0.19 based on the information available during the earnings call on May 5, 2016. Analyst had a consensus of $-0.75.During the same quarter in the previous year, the company posted $-0.47 EPS.

Many Wall Street Analysts have commented on Radius Health Inc. H.C. Wainwright Initiated Radius Health Inc on May 23, 2016 to “Buy”, Price Target of the shares are set at $55.Radius Health Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016. Radius Health Inc was Downgraded by Jefferies to ” Hold” on Feb 24, 2016.

Radius Health Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate is abaloparatide (BA058) a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch which the Company refers to as abaloparatide-TD. The Company’s clinical product portfolio also includes the investigational drug RAD1901 a selective estrogen receptor down regulator/degrader (SERD) and RAD140 a nonsteroidal selective androgen receptor modulator (SARM) for the treatment of breast cancer.

Leave a Reply

Radius Health Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Radius Health Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.